Virbac : Le temps est venu de se projeter au-delà de 2025
Après un exercice 2025 de transition au niveau des marges, Virbac présente, sur 2026-2027e, une visibilité assurée par plusieurs leviers opérationnels (la filiale US, le pipeline de lancements, le M&A, les gains de productivité industrielle) devant engendrer une hausse de 8%par an de l’EBIT sur 2026/27e. Nous réitérons notre opinion Surperformance et relevons notre objectif de cours à 409 € vs 395 € faisant ressortir un upside de 18%.Virbac is an independent veterinary pharmaceutical laboratory. Co. develops and provides veterinarians and farmers with medicines and vaccines that improve the health of food producing animals. Co. markets a range of products designed for pets and livestock. It offers seven types of products for companion animals (Parasiticides, Immunology, Antibiotics/dermatology, Specialties, Equine, Specialized pet food and Other products), and four types of products for food producing animals (Bovine parasiticides, Bovine products (excluding parasiticides), Pig/poultry antibiotics and Other products). Co. markets its products in the ethical (veterinarian) and OTC markets.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.